Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Starts Discussing Blood Law Amendment Focusing on Use of Blood-Derived iPS Cells, New Entrants into Blood Collection
April 26, 2018
- Patients Won’t Benefit without Change in Mindset among Researchers: AMED President
April 25, 2018
- ICER-Based Price Tweaks “Scientifically Difficult,” Impact on Cost Cuts Limited: Prof.
April 25, 2018
- Tap Data from “Specified Clinical Research” for Early Trial, Conditional Approval: JPMA Official
April 24, 2018
- Label Revision Ordered for Keytruda with Sclerosing Cholangitis as ADR
April 20, 2018
- MHLW Sees Solid Inquiry Numbers for Conditional Early Approval System: Official
April 19, 2018
- Generic Industry Asks for Govt Support for Continuous Manufacturing to Boost Int’l Competitiveness: Public-Private Confab
April 17, 2018
- No Company Supports New Price Maintenance Premium Scheme: FPMAJ Survey
April 17, 2018
- Pharma Leaders Air Grievances on Pricing Reform Package at New MHLW Confab
April 17, 2018
- Generic Drug Makers Required to Improve Package Inserts by Adding Information from Clinical Studies: MHLW Notification
April 17, 2018
- Xeljanz’s Ulcerative Colitis Use Up for MHLW Panel Review on April 27
April 16, 2018
- MHLW to Draft GL on Detailing Activities by Drug Reps as Early as Summer
April 13, 2018
- MHLW Compiles Drug Reuse Guide to Reduce Leftover Drug Solutions
April 13, 2018
- AZ’s PD-L1 Inhibitor Durvalumab Up for MHLW Panel Review on April 25
April 13, 2018
- MHLW to Issue Optimal Use Guidelines for Dupixent, Tecentriq
April 12, 2018
- MHLW Panel Starts Discussions on PMD Law Amendment; Will First Verify Results of Previous Amendment
April 12, 2018
- Chuikyo Holds 1st Listing Discussions since Overhaul, US Reference Prices Show Marked Declines after Rule Change
April 12, 2018
- Chuikyo Payer Rep Questions New Premium System for Cost-Based Pricing Method
April 12, 2018
- MOF Calls for Using CEA to Make Reimbursement Decisions for Pricy Drugs
April 12, 2018
- Pricing OK’ed for Dupixent, Tecentriq, Lynparza, and More; Parmodia Skips Listing Yet Again
April 11, 2018
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…